Navigation Links
Pediatrics Study Finds Children Taking ADHD Medications Did Not Suffer More Serious Heart Problems or Cardiovascular-related Death
Date:5/16/2011

WILMINGTON, Del., May 16, 2011 /PRNewswire/ -- Children taking medication for attention deficit hyperactivity disorder suffered no more from serious heart problems or heart-related deaths than those who were not taking ADHD medications, according to a study published online today in the journal, Pediatrics.

The study, co-authored by researchers at the University of Pennsylvania and HealthCore Inc., drew data from the largest population—241,417 children and adolescents—studied to date to evaluate cardiovascular problems and death associated with pediatric ADHD medication use.  The study also includes records involving both Medicaid and commercially insured children.

Case reports of sudden death in children and adolescents treated with these drugs have led some to worry they might increase the risk of serious cardiovascular events.  Previous studies have shown conflicting results.

"We found low rates of cardiovascular events and of cardiovascular-related deaths in those children and adolescents receiving ADHD medications," said lead author Sean Hennessy, PharmD, PhD , an associate professor of epidemiology at the University of Pennsylvania School of Medicine. "For kids who will benefit from ADHD treatment, the potential risk of a cardiovascular event should not dissuade parents or caregivers from giving a child or adolescent these drugs."

The study found no significant increases in rates of sudden death, heart attack and stroke in patients taking ADHD medications compared to those not taking medications.

Researchers used data on children and adolescents from 3-17 years old from a five-state Medicaid database, as well as the HealthCore Integrated Research Database™, which contains historical and current medical and pharmacy claims data from more than 44 million enrollees in Blue Cross and Blue Shield plans across 14 states. The study identified patients ages 3-17 on ADHD medications and tracked their health records during the period they were on the medications.

"A key strength of this study is that the study data reflected experiences of children and adolescents from a wide range of demographic and economic backgrounds –those from families receiving state Medicaid benefits and those from families with private health insurance," said Gregory Daniel, PhD, MPH , HealthCore vice president of government and academic research. "We were also able to combine insurance claims data with medical records to gain much more insight into whether or not risks of severe cardiovascular events and related mortality were elevated."

The study was based on Medicaid records from 1999-2003 and HealthCore Integrated Research Database™ records from 2001-2006, well before a 2008 recommendation from the American Heart Association that an electrocardiogram be performed before starting any child or teenager on stimulant medications.  The study showed that the use of ECGs during this study period, before the 2008 recommendation, were very low.

"It is interesting to note the lower incidence of cardiac-related events, especially when you consider that very few patients from this study were screened with an ECG prior to initiating therapy," said Mark J. Cziraky, PharmD,  FAHA, HealthCore vice president of industry sponsored research.  "This would likely  have removed more patients with higher cardiac risks from the pool of patients using ADHD medications, and would have potentially lowered the rate further."

The study was funded by Shire, a manufacturer of ADHD medications.

Other authors of the study included: Hedi Schelleman, PhD; Warren B. Bilker, PhD; Brian L. Strom, MD, MPH; Stephen E. Kimmel, MD, MSCE; Craig Newcomb, MS; and James P. Guevara, MD, MPH, all from the University of Pennsylvania.

About HealthCore

HealthCore, based in Wilmington, Del., is the clinical outcomes research subsidiary of WellPoint.  HealthCore has a team of highly experienced researchers including physicians, biostatisticians, pharmacists, epidemiologists, health economists and other scientists who study the real-world safety and effectiveness of drugs, medical devices and care management interventions. HealthCore offers insight on how to best use this data and communicates these findings to health care decision-makers to support evidence-based medicine, product development decisions, safety monitoring, coverage decisions, process improvement and overall cost-effective health care. For more information, go to www.healthcore.com.


'/>"/>
SOURCE HealthCore
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Mattel Childrens Hospital UCLA launches program in nanopediatrics
2. NewsRx Adds Pediatrics and Psychiatry Titles
3. Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia® (certolizumab pegol)
4. New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
5. ImmusanT Reports Positive Results from Nexvax2 Phase 1 Study in Celiac Disease
6. Study Shows Stents Are Superior to Balloons Alone for Patients With Deep Venous Thrombosis
7. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
8. Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
9. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
10. New Biomarkers Study Could Lead to Better Malaria Vaccine Design
11. Columbia engineering study links ozone hole to climate change all the way to the equator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):